WO1995032425A1 - Encoded combinatorial libraries - Google Patents
Encoded combinatorial libraries Download PDFInfo
- Publication number
- WO1995032425A1 WO1995032425A1 PCT/US1995/006392 US9506392W WO9532425A1 WO 1995032425 A1 WO1995032425 A1 WO 1995032425A1 US 9506392 W US9506392 W US 9506392W WO 9532425 A1 WO9532425 A1 WO 9532425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beads
- library
- reaction
- combinatorial
- encoded
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/0054—Means for coding or tagging the apparatus or the reagents
- B01J2219/00572—Chemical means
- B01J2219/00576—Chemical means fluorophore
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00592—Split-and-pool, mix-and-divide processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Definitions
- the field of this invention concerns combinatorial chemistry which involves the syntheses of one or more encoded combinatorial libraries where large numbers of products having varying compositions are obtained. This invention also relates to methods of encoding combinatorial libraries.
- the standard method for conducting a search is to screen a variety of pre-existing chemical moieties, for example, naturally occurring compounds or compounds which exist in synthetic libraries or databanks.
- the biological activity of the pre-existing chemical moieties is determined by applying the moieties to an assay which has been designed to test a particular property of the chemical moiety being screened, for example, a receptor binding assay which tests the ability of the moiety to bind to a particular receptor site.
- Nonpeptidic organic compounds such as peptide mimetics
- peptide mimetics can often surpass peptide ligands in affinity for a certain receptor of enzyme.
- An effective strategy for rapidly identifying high affinity biological ligands, and ultimately new and important drugs, requires rapid construction and screening of diverse libraries of non-peptidic structures containing a variety of structural units capable of establishing one or more types of interactions with a biological acceptor (e.g., a receptor or enzyme), such as hydrogen bonds, salt bridges, pi-complexation, hydrophobic effects, etc.
- a biological acceptor e.g., a receptor or enzyme
- a key unsolved problem in the area of generation and use of nonpeptide libraries is the generation and use of nonpeptide libraries is the elucidation of the structure of molecules selected from a library that show promising biological activity.
- An attempt to uncover the structures of peptides selected from a library using unique nucleotide sequence codes, which are synthesized in tandem with the peptide library, has been described by Brenner and Lerner (Brenner, S. and Lerner, R.A. Proc. Nat'l. Acad. Sci. USA, 1992 89 . 5381-5383).
- the nucleotide sequence of the code attached to each peptide must be amplifiable via the polymerase chain reaction (PCR).
- nucleotide synthesis techniques are not compatible with all of the synthetic techniques required for synthesis of many types of molecular libraries.
- the close proximity of nucleotide and synthetic test compound in the library which can result in interactions between these molecules interfering with the binding of the ligand with a target receptor of enzyme during the biological assay, also limits this approach.
- the nucleotide component of the library can also interfere during biological assays in a variety of other ways.
- Kerr et al. J, Am, Chem, Soc., 1993, 115, 2520-2531
- the peptide ligand and its coding strand in this library are covalently joined together, which allows isolation and sequence determination of pairs of synthetic test compound and corresponding code.
- the coding peptide may interfere with the screening assay.
- PCT/US93/09345 describes a method of identifying actives in a
- combinatorial library by attaching multiple tags in a predetermined binary coding system.
- PCT/HU93/0030 describes fluorescently labeled sub-library peptide kits for use in peptide synthesis.
- PCT/US94/06078 describes methods of encoding combinatorial libraries using polymeric sequences.
- This invention relates to a method for identifying compounds having desired characteristics and identifying essential moieties in a lead structure which comprises preparing one or more encoded combinatorial libraries from a specified set of reaction sequences and testing compounds therein for biological activity.
- This invention also relates to a method of encoding a single registry in each combinatorial library of a series of combinatorial libraries and combinatorial libraries with a single encoded registry.
- This invention also relates to a method of encoding combinatorial libraries which comprises utilization of tagged beads.
- This invention also relates to a method of encoding each choice of a combinatorial library and combinatorial libraries encoded thereby.
- This invention also relates to beads with fluorescently labeled identifiers attached thereto.
- beads means any solid support material capable of providing a base for combinatorial syntheses and capable of being processed by flow cytometry, such as 1 to 2% crosslinked polystyrene, polyacrylamide, polyethylene glycol polystyrene co-polymer, preferably Tentagel 10 to 100 micron particles, most preferably Tentagel 10-30 micron particles.
- sort means to form beads into groups which have a common tagging aspect by flow cytometry.
- the term "separate” or “split” when referring to encoded beads or beads of a combinatorial library means to partition the mixture of beads into groups, each group thereinby containing a mixture, preferably a statistical mean of all members.
- the term "tag”, unless otherwise indicated, means an encoding characteristic of a bead or group of beads which is capable of being sorted by flow cytometry, such as differences in size, differences in material composition, differences in flow properties, a single fluorescent marker or, preferably, a fluorescent label identifier.
- fluorescent label identifier or "identifier” means a coding label attached to a bead or group of beads either by adding ratios of a fluorophore and a non-fluorophore or by adding multiple, preferably two, different fluorophores in varying ratios.
- the term "intensity-differentiated” means an identifier (as used herein) in which varying ratios of a fluorophore and a non-fluorophore are added to a bead or group of beads.
- the term "choice” means the alternative variables for a given stage in a combinatorial synthesis (not limited to peptide chemistry), such as reactant, reagent, reaction conditions, and combinations thereof.
- stage corresponds to a step in the sequential synthesis of a compound or ligand; the compound or ligand being the final product of a combinatorial synthesis.
- registration has the same meaning as the term "stage” as indicated above.
- a series of combinatorial libraries are prepared, each individual library being prepared from substantially the same specified set of reaction sequences, therein encoding a single registry within each combinatorial library and analyzing according to mixtures of compounds with a homogeneous registry.
- the specific encoded registry of any library will be different from the other libraries and the number of libraries prepared will equal the number of registries in a single library.
- the number of readily identifiable groups of beads will correspond to the number of choices in the first registry, the entirety of each group is entered into a separate container.
- the beads will usually be divided up into groups of at least one bead each, usually a plurality of beads, generally 1000 or more, and may be 10 5 or more depending on the total number of registries involved in the library.
- the same reaction may be carried out in 2 or more containers to enhance the proportion of product having a particular reaction in a particular registry as compared to the other choices.
- one or more of the registries may involve a portion of the beads being set aside and undergoing no reaction, so as to enhance the variability associated with the final product.
- batches may be taken along different synthetic pathways. The library thus prepared will contain tagged beads which identify the reaction sequence of the first registry only.
- a combinatorial library containing tagged beads which identify the reaction sequence of the first registry only can be prepared as outlined in Scheme 1 below.
- Scheme 1 outlines the preparation of a combinatorial library in which only the first registry has been encoded.
- beads with attached fluorescently labeled identifiers are derivatized with a linker that allows for cleavage of the compound to be tested.
- each group of similarly tagged beads is entered into a separate container and subjected to specified reaction conditions (or variable building blocks, as used herein) to form the first registry.
- specified reaction conditions or variable building blocks, as used herein
- the beads In carrying out the synthesis to prepare the second library, one will preferably begin with the same number of beads as used in the first library, said beads may be tagged in a similar manner as in the first library.
- the beads for use in the second library are first combined into a single mixture and then separated according to the number of choices for the first registry.
- schemeSchoices for each registry of the second library and all subsequent libraries will be substantially the same as the synthetic schemeSchoices of the corresponding registry in the first library.
- the reaction(s) may wish to wash the beads free of any reagent, followed by combining all of the beads into a single mixture and then separating the beads according to the number choices in the third registry of the first library. This procedure of dividing beads, followed by the synthetic scheme(s) ⁇ choice(s) from the corresponding registry of the first library, and then recombining the beads is iterated until the second library in completed.
- the library thus prepared will contain tagged beads which identify the reaction sequence of the second registry only.
- a combinatorial library containing tagged beads which identify the reaction sequence of the second registry only can be prepared as outlined in Scheme 2 below.
- step 4 Deprotect FMOC; couple FMOC-NHCHR B1-BN CO 2 H. 5) Combine and separate. 6) Repeat step 4 and 5, except replace FMOC-NHCHR B 1-BN CO 2 H with FMOC-NHCHR C1-CN CO 2 H, ... FMOC-NHCHR X1-XN CO 2 H until the synthesis is complete.
- Scheme 2 outlines the preparation of a combinatorial library in which only the second registry has been encoded.
- beads with attached fluorescent label identifiers are first combined into a single mixture and then separated into groups according to the number of choices in the first registry of the first library . Subsequently, each group is entered into a separate container and subjected to the same reaction conditions of the first registry of the first library to form the first registry of the second library. Once the reaction(s) is complete the beads are combined into a single mixture and then sorted into groups according to similarly tagged beads. Preferably this combination of beads will be sorted using flow cytometry.
- Each group of similarly tagged beads is entered into a separate container and subjected to the same reaction conditions of the second registry of the first library to form the second registry of the second library.
- the beads are combined into a single mixture and then separated according to the number of choices in the third registry of the first library and reacted accordingly.
- This procedure of dividing the beads, fo by subjection to specified reaction conditions from the corresponding ⁇ of the first library, and then recombining the beads is iterated until the second horary is completed.
- the completed library is then tested for biological activity. Information on the relative activities of mixtures of the compounds with a homogeneous second registry is obtained from this library.
- the above process is repeated to prepare subsequent libraries (when desired), provided that the sorting procedure is performed prior to a different synthetic stage in each library.
- the combinatorial libraries thus prepared will contain tagged beads which identify the reaction sequence of a single registry only. Further, the identifiable ⁇ encoded registry in each combinatorial library will be different. Subsequent Combinatorial Libraries
- each library is tested separately for biological activity.
- testing for biological activity or "testing for desired
- the compounds of a library may be tested on the beads, for example by bio-panning using a soluble receptor assay, and the activities analyzed preferably by flow cytometry.
- the contents of the library may be sorted preferably by flow cytometry and the compounds tested on the beads, or the sorted compounds cleaved from the beads prior to testing.
- Analysis of the first combinatorial library will yield the SAR of variable building block A.
- Analysis of the second combinatorial library will yield the SAR of variable building block B.
- Analysis of the third combinatorial library will yield the SAR of variable building block C.
- Analysis of the SARs of the three variable building blocks (A, B and C) will identify desired reaction sequences and suggest multiple lead structures.
- fluorescent label identifiers when referring to
- flow cytometers are able to sort beads that differ in fluorescence intensity by a factor of 2.
- the principles of flow cytometry and general methods for using flow cytometry are described in Grogan and Collins, Guide to Flow Cytometry Methods, Pub: Marcel Dekker, Inc. (1990).
- intensity-differentiated fluorophore-labeled beads can be prepared by the method outlined in Scheme 3 below and in the Examples.
- R is a fluorescent tag T 1 or a doping agent
- D and R' is a fluorescent tagT 2 or a doping agent D, provided that when R is D, R' is other that D.
- a sample of beads is derivatized with a linker, preferably ⁇ -Boc-FMOC lysine, by standard coupling chemistry.
- a linker preferably ⁇ -Boc-FMOC lysine
- a benzyl alcohol linker such as used with the Wang linker or a benzyl halide linker such as used with the Merrifield linker, or a benzhydryl amine linker as used with the Rink linker can be attached to the beads by the formation of ethers by alkylation of alcohols, alkylation or arylation by Friedl Crafts chemistry, the formation of biaryls by palladium mediated cross-coupling chemistry or by standard amide coupling chemistry.
- a mono- deprotection step such as 20% piperdine/ DMF, for removal of an FMOC is performed.
- the beads are then divided into N pools.
- Pool 1 is derivatized with a fluorophore, such as pyrene butyric acid.
- Pool 2 is derivatized with a 1:3 mixture of a fluorophore, such as pyrene butyric acid, and a non-fluorophore (hereinafter a "doping agent"), such as butyric acid or a different fluorophore, such as perylene butyric acid.
- a fluorophore such as pyrene butyric acid
- a non-fluorophore hereinafter a "doping agent”
- Pool N is derivatized with a 1: 3 (N-1) ratio of a fluorophore, such as pyrene butyric acid, and a doping agent, such as butyric acid or a different fluorophore, such as perylene butyric acid.
- a fluorophore such as pyrene butyric acid
- a doping agent such as butyric acid or a different fluorophore, such as perylene butyric acid.
- Each of these pools of beads can be differentiated from any other pool of beads by flow cytometry.
- Each pool of beads may also be differentiated from one another by inspection with the unaided eye, however fewer variables could be encoded this way.
- different fluorophores with different absorption and emittance wavelengths and multiple fluorophores could be encoded by fluorescence quenching to encode additional variables.
- the use of multiple fluorophores, the ratio of which is the identifier has several advantages including the ability to greatly increases the number of variables that can be identified by using the same number of tags and enabling analysis independent of bead size.
- the same strategy can be applied to prepare beads that can be used to discriminate between library members with redundant molecular weights by fluorescence, preferably by starting with beads with at least 50 pmoles of linker.
- a single combinatorial library is prepared, each choice therein being encoded by a tag, preferably using fluorescent label identifiers, and tested for biological activity, preferably without mixing the final pools.
- the “Combine and Split protocol” is utilized to synthesize encoded beads, preferably with fluorescent label identifiers attached thereto.
- the “Combine and Split protocol” is advantageous in that it eliminates the need to resynthesize, or parallel synthesize, libraries containing only one or two fluorescent tags. This aspect of the invention is especially attractive from a practical point of view since the encoded beads can be prepared in bulk, prior to the actual synthesis of combinatorial libraries.
- An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
- An additionally preferred aspect of this invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers and to pharmaceutically active compounds identified by such combinatorial library.
- An additionally preferred aspect of this invention relates to combinatorial libraries prepared using beads encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
- An additionally preferred aspec his invention relates to combinatorial libraries in which each choice therein is encoded by fluorescent label identifiers, wherein said beads were obtained by the Combine and Split protocol, and to pharmaceutically active compounds identified by such combinatorial library.
- Y 1 is encoded by Y 2 is encoded by Y 3 is encoded by T 1c T 2c T 3c
- the above T 1 a Registry The above T 2a Registry
- the above T 3a Registry can be described as can be described as can be described as can be described as can be described as
- Z 1 is encoded by Z 2 is encoded by Z 3 is encoded by T 1a T 2a T 3a
- T 1 b P 2 is encoded by T 2b
- Scheme 4 outlines the preparation of a combinatorial library in which each choice therein is encoded by a unique identifier.
- untagged beads are encoded with the first identifier (as described in Scheme 3).
- the encoded beads are combined into a single mixture and then separated into groups according to the number of permutations of the second identifier.
- the beads are then encoded with the second identifier. (The above encoding process is repeated until groups of encoded beads of desired size is obtained).
- the beads encoded with the second identifier are combined into a single mixture and then separated into groups according to the number of permutations of the third identifier.
- the beads are then encoded with the third identifier.
- Encoded beads prepared according to the above methods and said methods represent preferred embodiments of the claimed invention.
- the beads thus prepared are maintained in separate homogeneous pools of like identifiers according to the third identifier and subjected to the first stage (or registry as used herein) of specified reaction conditions.
- the choices of the first registry are thereinby encoded by the third identifier.
- the beads are then combined and sorted, preferably by flow cytometry, into homogeneous pools of like identifiers according to the first identifier.
- the beads thus obtained are maintained in separate pools and subjected to the second stage of specified reaction conditions.
- the choices of the second registry are thereinby encoded by the first identifier.
- the beads are then combined and sorted, preferably by flow cytometry, into
- the beads thus obtained are maintained in separate pools and subjected to the third stage of specified reaction conditions.
- the choices of the third registry are thereinby encoded by the second identifier.
- the beads are then combined and separated into groups according to the number of choices of the forth stage and subjected to the forth stage of specified reaction conditions.
- the pools of beads thus obtained are maintained in these separate groups and tested for biological activity.
- the choices of the forth registry are thereinby separately maintained.
- each of these groups are separately tested for biological activity and analyzed, preferably by flow cytometry or by cleavage of compounds from individual groups or from smaller sets of individual groups.
- the exact reaction history of each active can be identified by reading the unique identifier from the corresponding bead.
- an active compound is found in group 2 then one could analyze the individual bead by fluorescence detection. If T 3c , T 2a , T 2b were present on the bead, then the reaction history of the active structure is: Y 3 -Z 2 -P 2 -Q 2 .
- a bifunctional linker such as e-Boc-FMOC-L- lysine (8.4 g, 6 eq., 18 mmol, Novabiochem), an amide coupling agent such as diisopropyl carbodiimide ( 2.3 g, 2.8 ml, 6 eq., 18 mmol, Aldrich) is added to Polyethylene glycol-linked to cross-linked polystyrene beads (Tentagel M NH 2 , 10 micron particle size, 15.0 g, 3 mmol, Rapp Polymere) suspended in a suitable solvent such as N-methyl pyrrolidine (300 ml) and is agitated overnight The reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 100 ml).
- a suitable solvent such as N-methyl pyrrolidine
- the lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (1.7 g, 6 eq., 6 mmol, Aldrich) and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the beads are then agitated in 25% TFA/CH 2 CI 2 (100 ml) for 2 h removing the Boc protective group.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
- the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 100 ml), then air dried.
- the beads are then re suspended in THF ( 100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
- the beads ( 5 g), as prepared in Procedure B, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- glyine (1.8 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L- glyine (1.8 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Procedure D The lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (0.43 g, 1.5 eq., 1.5 mmol), and a doping agent such as butyric acid (0.4 g, 0.41 ml, 4.5 eq., 4.5 mmol) in 1:3 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
- a fluorophore such as 1-pyrene butyric acid (0.43 g, 1.5 eq., 1.5 mmol)
- a doping agent such as butyric acid (0.4 g, 0.41 ml, 4.5 eq., 4.5 mmol) in 1:3 stoichiometry
- reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the beads are then agitated in 25% TFA/ CH 2 CI 2 (100 ml) for 2 h removing the Boc protective group.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
- the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 100 ml), then air dried.
- the beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
- the beads ( 5 g), as prepared in Procedure D, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- alanine (1.9 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L- alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the lysine derivatized beads (5.0 g), as described in Procedure A, are suspended in N-methyl pyrrolidine (100 ml), then a fluorophore such as 1-pyrene butyric acid (0.173 g, 0.6 eq., 0.6 mmol), and a doping agent such as butyric acid (0.48 g, 0.49 ml, 5.4 eq., 5.4 mmol) in 1:9 stoichiometry, and diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) are added, and the reaction is agitated for 3 hours.
- a fluorophore such as 1-pyrene butyric acid (0.173 g, 0.6 eq., 0.6 mmol)
- a doping agent such as butyric acid (0.48 g, 0.49 ml, 5.4 eq., 5.4 mmol) in 1:9 stoichiometry,
- Th e reaction is filtered through a glass frit under aspirator pressure, washed with DMH ( 5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the beads are then agitated in 25% TFA/ CH 2 CI 2 (100 ml) for 2 h removing the Boc protective group.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
- the beads are then reacted with a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- a linker group such as the t-butyl dimethyl silyl ether of 4-(methyl hydroxy-phenyl) acetic acid ( 1.3 g, 6 mmol), diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) in N-methyl pyrrolidine (100 ml) overnight.
- the reaction is filtered through a glass frit under aspirator pressure and is washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 100 ml), then air dried.
- the beads are then resuspended in THF (100 ml), and a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- a desilylating agent such as tetrabutyl ammonium fluoride(6 ml, 1.0 M solution, 6 mmol, Aldrich) / ammonium acetate (0.92 g, 12 mmol) is used to deprotect the silyl ether producing the desired benzyl alcohol derivative.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried.
- the beads ( 5 g), as prepared in Procedure F, are then suspended in N- methyl pyrrolidine (100 ml) and is then reacted with a monomer such as FMOC-L- phenylalanine (2.3 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L- phenylalanine (2.3 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool H1 is reacted with a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-glyine (1.8 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool H2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Procedure J The beads obtained from Procedure I are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence. Sublibrary components have the same first amino acid of the tripeptide.
- Sublibrary J1 consists of Gly-X-X or Gly-Gly-Gly, Gly-Gly-Ala, Gly-Gly-Phe, Gly- Ala- Gly, Gly-Ala-Ala, Gly-Ala-Phe, Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe.
- Sublibrary J2 consists of Ala-X-X or Ala-Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Ala- Ala- Gly, Ala-Ala- Ala, Ala-Ala-Phe, Ala-Phe-Gly, Ala-Phe-Ala, Ala-Phe-Phe
- Sublibrary J3 consists of Phe-X-X or Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly-Phe, Phe- Ala- Gly, Phe-Ala-Ala, Phe-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe-Phe-Phe-Phe
- Pool M2 is reacted with a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- a monomer such as FMOC-L-alanine (1.9 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- Pool M3 is reacted with a monomer such as FMOC-L-phenylalanine (2.3 g, 6 eq., 6 mmol).
- Diisopropyl carbodiimide (0.76 g, 0.94 ml, 6 mmol) is added, and the reaction is agitated for 3 hours.
- the reaction is filtered through a glass frit under aspirator pressure, washed with DMF (5 x 30 ml), then CH 2 CI 2 (5 x 30 ml), then air dried. This procedure is repeated until the reaction is complete by the Kaiser ninhydrin test.
- the beads obtained from Procedure M are then combined and sorted by flow cytometry into different sublibraries differentiated by the differences in intensity of fluorescence.
- Sublibrary components have the same second amino acid of the tripeptide.
- Sublibrary N1 consists of X-Gly-X or Gly-Gly-Gly, Gly-Gly- Ala, Gly-Gly-Phe, Ala- Gly-Gly, Ala-Gly-Ala, Ala-Gly-Phe, Phe-Gly-Gly, Phe-Gly-Ala, Phe-Gly- Phe
- Sublibrary N2 consists of X-Ala-X or Gly-Ala-Gly, Gly- Ala- Ala, Gly-Ala-Phe, Ala- Ala- Gly, Ala- Ala- Ala, Ala-Ala-Phe, Phe-Ala-Gly, Phe-Ala-Ala, Phe-Ala- Phe
- Sublibrary N3 consists of X-Phe-X or Gly-Phe-Gly, Gly-Phe-Ala, Gly-Phe-Phe, Ala-Phe- Gly, Ala-Phe-Ala, Ala-Ala-Phe, Phe-Phe-Gly, Phe-Phe-Ala, Phe- Phe-Phe-Phe
- the beads obtained from Procedure P are then combined and sorted by flow cytometry into different pools differentiated by the differences in intensity of fluorescence.
- the pools of beads obtained from Procedure Q are already sorted into sublibraries in which the third amino acid of each component is the same the same amino acid of the tripeptide.
- Sublibrary Q1 consists of X-X-Gly or Gly-Gly-Gly, Gly-Ala-Gly, Gly-Phe-Gly,
- Sublibrary Q2 consists of X-X-Ala or Gly-Gly- Ala, Gly- Ala- Ala, Gly-Phe- Ala,
- Ala-Gly- Ala Ala- Ala- Ala, Ala-Phe-Ala, Phe-Gly-Ala, Phe-Ala-Ala, Phe-
- Sublibrary Q3 consists of X-X-Phe or Gly-Gly-Phe, Gly-Ala-Phe, Gly-Phe-Phe,
- Example 1 The methods of Example 1 are used except that the doping reagent is replaced by a second fluorophore such as perylene butyric acid.
- a second fluorophore such as perylene butyric acid.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7530459A JPH10500951A (en) | 1994-05-23 | 1995-05-23 | Coded combinatorial library |
US08/537,752 US6210900B1 (en) | 1995-05-23 | 1995-05-23 | Method of encoding a series of combinatorial libraries and developing structure activity relationships |
EP95920576A EP0763202A4 (en) | 1994-05-23 | 1995-05-23 | Encoded combinatorial libraries |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24779394A | 1994-05-23 | 1994-05-23 | |
US08/247,793 | 1994-05-23 | ||
US26733394A | 1994-06-28 | 1994-06-28 | |
US08/267,333 | 1994-06-28 | ||
US38254295A | 1995-02-01 | 1995-02-01 | |
US08/382,542 | 1995-02-01 | ||
US41043695A | 1995-03-23 | 1995-03-23 | |
US08/410,436 | 1995-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995032425A1 true WO1995032425A1 (en) | 1995-11-30 |
Family
ID=27500266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/006392 WO1995032425A1 (en) | 1994-05-23 | 1995-05-23 | Encoded combinatorial libraries |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0763202A4 (en) |
JP (1) | JPH10500951A (en) |
WO (1) | WO1995032425A1 (en) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866341A (en) * | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
WO1999006839A1 (en) * | 1997-08-01 | 1999-02-11 | Novalon Pharmaceutical Corporation | Method of identifying and developing drug leads |
WO1999049315A1 (en) * | 1998-03-24 | 1999-09-30 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using facs |
WO1999064867A1 (en) * | 1997-12-04 | 1999-12-16 | Amersham Pharmacia Biotech Uk Limited | Multiple assay method |
US6054047A (en) * | 1998-03-27 | 2000-04-25 | Synsorb Biotech, Inc. | Apparatus for screening compound libraries |
WO2000032542A1 (en) * | 1998-11-30 | 2000-06-08 | The University Of Queensland | Carriers for combinatorial compound libraries |
WO2000061281A1 (en) * | 1999-04-09 | 2000-10-19 | Glaxo Group Limited | Encoding scheme for solid phase chemical libraries |
WO2001080622A2 (en) * | 2000-04-26 | 2001-11-01 | Streamline Proteomics | Apparatus and methods for assays of one or more analytes |
WO2002064829A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting genetic characteristics |
WO2002065123A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting protein characteristics |
US6489116B2 (en) | 2000-01-24 | 2002-12-03 | Phylos, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
US6492125B2 (en) * | 1998-09-03 | 2002-12-10 | Trellis Bioscience, Inc. | Method to assess library X library interactions |
US6506342B1 (en) * | 1997-06-19 | 2003-01-14 | Robert D. Frankel | Tracking apparatus and method for use with combinatorial synthesis processes |
US6602685B1 (en) | 1998-08-17 | 2003-08-05 | Phylos, Inc. | Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules |
US6607921B1 (en) | 1998-03-27 | 2003-08-19 | Ole Hindsgaul | Methods for screening compound libraries |
US6613575B1 (en) | 1998-03-27 | 2003-09-02 | Ole Hindsgaul | Methods for screening compound libraries |
US6627453B1 (en) | 1998-03-27 | 2003-09-30 | Ole Hindsgaul | Methods for screening compound libraries |
WO2005061094A1 (en) | 2003-12-22 | 2005-07-07 | Versamatrix A/S | Identification of encoded beads |
US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
WO2010109168A2 (en) | 2009-03-23 | 2010-09-30 | Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) | Angiogenesis methods, medicaments and agents |
US7869011B2 (en) | 2003-12-22 | 2011-01-11 | Novo Norkisk A/S | Apparatus and methods for analysis and sorting of particles such as polymer beads |
WO2011098484A1 (en) | 2010-02-09 | 2011-08-18 | Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) | Trichodysplasia spinulosa- associated polyomavirus (tsv) |
WO2012093258A2 (en) | 2011-01-05 | 2012-07-12 | Imperial Innovations Limited | Treatment and screening |
US8222047B2 (en) | 2008-09-23 | 2012-07-17 | Quanterix Corporation | Ultra-sensitive detection of molecules on single molecule arrays |
US8236574B2 (en) | 2010-03-01 | 2012-08-07 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
EP2573563A1 (en) | 2007-12-20 | 2013-03-27 | Heptares Therapeutics Limited | Screening |
US8415171B2 (en) | 2010-03-01 | 2013-04-09 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
US8460879B2 (en) | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US8703915B2 (en) | 2009-06-22 | 2014-04-22 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
US8748182B2 (en) | 2007-12-08 | 2014-06-10 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
US8785135B2 (en) | 2007-03-22 | 2014-07-22 | Heptares Therapeutics Limited | Mutant G-protein coupled receptors and methods for selecting them |
US9081020B2 (en) | 2008-02-11 | 2015-07-14 | Heptares Therapeutics Limited | Mutant proteins and methods for selecting them |
US9110025B2 (en) | 2010-03-01 | 2015-08-18 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
WO2016116760A2 (en) | 2015-01-21 | 2016-07-28 | Cancer Research Technology Limited | Inhibitors |
US9678068B2 (en) | 2010-03-01 | 2017-06-13 | Quanterix Corporation | Ultra-sensitive detection of molecules using dual detection methods |
WO2017129998A1 (en) | 2016-01-29 | 2017-08-03 | Heptares Therapeutics Limited | G proteins |
US9809838B2 (en) | 2007-08-30 | 2017-11-07 | Trustees Of Tufts College | Methods for determining the concentration of an analyte in solution |
US9932626B2 (en) | 2013-01-15 | 2018-04-03 | Quanterix Corporation | Detection of DNA or RNA using single molecule arrays and other techniques |
US9952237B2 (en) | 2011-01-28 | 2018-04-24 | Quanterix Corporation | Systems, devices, and methods for ultra-sensitive detection of molecules or particles |
US10393759B2 (en) | 2011-04-12 | 2019-08-27 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
WO2020049130A1 (en) | 2018-09-05 | 2020-03-12 | Valerie Nicholas Carl Kristoffer | Methods |
US11237171B2 (en) | 2006-02-21 | 2022-02-01 | Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002542463A (en) * | 1999-04-15 | 2002-12-10 | バーチャル・アレイズ・インコーポレーテッド | Combinatorial chemical library with indices at code locations |
AU2001232231A1 (en) * | 2000-02-07 | 2001-08-20 | Kyowa Medex Co., Ltd | Method for detecting substance |
-
1995
- 1995-05-23 WO PCT/US1995/006392 patent/WO1995032425A1/en not_active Application Discontinuation
- 1995-05-23 JP JP7530459A patent/JPH10500951A/en active Pending
- 1995-05-23 EP EP95920576A patent/EP0763202A4/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
NATURE, Volume 354, issued 07 November 1991, LAM et al., "A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity", pages 82-84. * |
PROC. NATL. ACAD. SCI. U.S.A., Volume 90, issued December 1993, OHLMEYER et al., "Complex Synthetic Chemical Libraries Indexed with Molecular Tags", pages 10922-10926. * |
PROC. NATL. ACAD. SCI. U.S.A., Volume 90, issued November 1993, NEEDELS et al., "Generation and Screening of an Oligonucleotide-Encoded Synthetic Peptide Library", pages 10700-10704. * |
See also references of EP0763202A4 * |
Cited By (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866341A (en) * | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
US6506342B1 (en) * | 1997-06-19 | 2003-01-14 | Robert D. Frankel | Tracking apparatus and method for use with combinatorial synthesis processes |
WO1999006839A1 (en) * | 1997-08-01 | 1999-02-11 | Novalon Pharmaceutical Corporation | Method of identifying and developing drug leads |
WO1999064867A1 (en) * | 1997-12-04 | 1999-12-16 | Amersham Pharmacia Biotech Uk Limited | Multiple assay method |
WO1999049315A1 (en) * | 1998-03-24 | 1999-09-30 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using facs |
US6455263B2 (en) | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
US6355163B2 (en) | 1998-03-27 | 2002-03-12 | Ole Hindsgaul | Apparatus for screening compound libraries |
US6607921B1 (en) | 1998-03-27 | 2003-08-19 | Ole Hindsgaul | Methods for screening compound libraries |
US6387257B1 (en) | 1998-03-27 | 2002-05-14 | Ole Hindsgaul | Apparatus for screening compound libraries |
US6395169B1 (en) | 1998-03-27 | 2002-05-28 | Ole Hindgual | Apparatus for screening compound libraries |
US6723235B2 (en) | 1998-03-27 | 2004-04-20 | Ole Hindsgaul | Apparatus for screening compound libraries |
US6720190B1 (en) | 1998-03-27 | 2004-04-13 | Ole Hindsgaul | Methods for screening compound libraries |
US6054047A (en) * | 1998-03-27 | 2000-04-25 | Synsorb Biotech, Inc. | Apparatus for screening compound libraries |
US6656739B2 (en) | 1998-03-27 | 2003-12-02 | Ole Hindsgaul | Methods for screening compound libraries |
US6613575B1 (en) | 1998-03-27 | 2003-09-02 | Ole Hindsgaul | Methods for screening compound libraries |
US6649415B1 (en) | 1998-03-27 | 2003-11-18 | Ole Hindsgaul | Methods for screening compound libraries |
US6627453B1 (en) | 1998-03-27 | 2003-09-30 | Ole Hindsgaul | Methods for screening compound libraries |
US6602685B1 (en) | 1998-08-17 | 2003-08-05 | Phylos, Inc. | Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules |
US6492125B2 (en) * | 1998-09-03 | 2002-12-10 | Trellis Bioscience, Inc. | Method to assess library X library interactions |
WO2000032542A1 (en) * | 1998-11-30 | 2000-06-08 | The University Of Queensland | Carriers for combinatorial compound libraries |
WO2000061281A1 (en) * | 1999-04-09 | 2000-10-19 | Glaxo Group Limited | Encoding scheme for solid phase chemical libraries |
US6489116B2 (en) | 2000-01-24 | 2002-12-03 | Phylos, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
WO2001080622A3 (en) * | 2000-04-26 | 2012-02-02 | Streamline Proteomics | Apparatus and methods for assays of one or more analytes |
WO2001080622A2 (en) * | 2000-04-26 | 2001-11-01 | Streamline Proteomics | Apparatus and methods for assays of one or more analytes |
WO2002064829A3 (en) * | 2001-02-13 | 2002-12-12 | Smartbead Technologies Ltd | Biochemical method and apparatus for detecting genetic characteristics |
WO2002065123A3 (en) * | 2001-02-13 | 2002-12-12 | Smartbead Technologies Ltd | Biochemical method and apparatus for detecting protein characteristics |
WO2002065123A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting protein characteristics |
WO2002064829A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting genetic characteristics |
WO2005061094A1 (en) | 2003-12-22 | 2005-07-07 | Versamatrix A/S | Identification of encoded beads |
US7869011B2 (en) | 2003-12-22 | 2011-01-11 | Novo Norkisk A/S | Apparatus and methods for analysis and sorting of particles such as polymer beads |
US8460878B2 (en) | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for detecting cells and cellular components in small defined volumes |
US10261089B2 (en) | 2006-02-21 | 2019-04-16 | Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US11874279B2 (en) | 2006-02-21 | 2024-01-16 | Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US9395359B2 (en) | 2006-02-21 | 2016-07-19 | Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US8492098B2 (en) | 2006-02-21 | 2013-07-23 | The Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of reaction components that affect a reaction |
US8460879B2 (en) | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US11237171B2 (en) | 2006-02-21 | 2022-02-01 | Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US11673938B2 (en) | 2007-03-22 | 2023-06-13 | Heptares Therapeutics Limited | Mutant G-protein coupled receptors and methods for selecting them |
US8785135B2 (en) | 2007-03-22 | 2014-07-22 | Heptares Therapeutics Limited | Mutant G-protein coupled receptors and methods for selecting them |
US9809838B2 (en) | 2007-08-30 | 2017-11-07 | Trustees Of Tufts College | Methods for determining the concentration of an analyte in solution |
US8748182B2 (en) | 2007-12-08 | 2014-06-10 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
EP2573563A1 (en) | 2007-12-20 | 2013-03-27 | Heptares Therapeutics Limited | Screening |
US8790933B2 (en) | 2007-12-20 | 2014-07-29 | Heptares Therapeutics Limited | Screening |
US9260505B2 (en) | 2007-12-20 | 2016-02-16 | Heptares Therapeutics Limited | Methods for screening for binding partners of G-protein coupled receptors |
US10126313B2 (en) | 2007-12-20 | 2018-11-13 | Heptares Therapeutics Limited | Methods for screening for binding partners of G-protein coupled receptors |
US9081020B2 (en) | 2008-02-11 | 2015-07-14 | Heptares Therapeutics Limited | Mutant proteins and methods for selecting them |
US8222047B2 (en) | 2008-09-23 | 2012-07-17 | Quanterix Corporation | Ultra-sensitive detection of molecules on single molecule arrays |
US8846415B2 (en) | 2008-09-23 | 2014-09-30 | Quanterix Corporation | Ultra-sensitive detection of molecules on single molecule arrays |
WO2010109168A2 (en) | 2009-03-23 | 2010-09-30 | Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) | Angiogenesis methods, medicaments and agents |
US8703915B2 (en) | 2009-06-22 | 2014-04-22 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
WO2011098484A1 (en) | 2010-02-09 | 2011-08-18 | Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) | Trichodysplasia spinulosa- associated polyomavirus (tsv) |
US9678068B2 (en) | 2010-03-01 | 2017-06-13 | Quanterix Corporation | Ultra-sensitive detection of molecules using dual detection methods |
US10725032B2 (en) | 2010-03-01 | 2020-07-28 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US9482662B2 (en) | 2010-03-01 | 2016-11-01 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US8236574B2 (en) | 2010-03-01 | 2012-08-07 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US9846155B2 (en) | 2010-03-01 | 2017-12-19 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
US11619631B2 (en) | 2010-03-01 | 2023-04-04 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US9551663B2 (en) | 2010-03-01 | 2017-01-24 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
US9310360B2 (en) | 2010-03-01 | 2016-04-12 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US9110025B2 (en) | 2010-03-01 | 2015-08-18 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
US8415171B2 (en) | 2010-03-01 | 2013-04-09 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
US10989713B2 (en) | 2010-03-01 | 2021-04-27 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
WO2012093258A2 (en) | 2011-01-05 | 2012-07-12 | Imperial Innovations Limited | Treatment and screening |
US9952237B2 (en) | 2011-01-28 | 2018-04-24 | Quanterix Corporation | Systems, devices, and methods for ultra-sensitive detection of molecules or particles |
US11112415B2 (en) | 2011-01-28 | 2021-09-07 | Quanterix Corporation | Systems, devices, and methods for ultra-sensitive detection of molecules or particles |
US10393759B2 (en) | 2011-04-12 | 2019-08-27 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
US11275092B2 (en) | 2011-04-12 | 2022-03-15 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
US10640814B2 (en) | 2013-01-15 | 2020-05-05 | Quanterix Corporation | Detection of DNA or RNA using single molecule arrays and other techniques |
US9932626B2 (en) | 2013-01-15 | 2018-04-03 | Quanterix Corporation | Detection of DNA or RNA using single molecule arrays and other techniques |
US10808031B2 (en) | 2015-01-21 | 2020-10-20 | Cancer Research Technology Limited | Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis |
WO2016116760A2 (en) | 2015-01-21 | 2016-07-28 | Cancer Research Technology Limited | Inhibitors |
US11919959B2 (en) | 2015-01-21 | 2024-03-05 | Cancer Research Technology Limited | Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis |
US10738287B2 (en) | 2016-01-29 | 2020-08-11 | Heptares Therapeutics Limited | G proteins |
US11339383B2 (en) | 2016-01-29 | 2022-05-24 | Heptares Therapeutics Limited | G proteins |
WO2017129998A1 (en) | 2016-01-29 | 2017-08-03 | Heptares Therapeutics Limited | G proteins |
WO2020049130A1 (en) | 2018-09-05 | 2020-03-12 | Valerie Nicholas Carl Kristoffer | Methods |
Also Published As
Publication number | Publication date |
---|---|
EP0763202A4 (en) | 1998-12-09 |
JPH10500951A (en) | 1998-01-27 |
EP0763202A1 (en) | 1997-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995032425A1 (en) | Encoded combinatorial libraries | |
US6210900B1 (en) | Method of encoding a series of combinatorial libraries and developing structure activity relationships | |
Lebl et al. | One‐bead–one‐structure combinatorial libraries | |
Früchtel et al. | Organic chemistry on solid supports | |
US5541061A (en) | Methods for screening factorial chemical libraries | |
AU686186B2 (en) | Topologically segregated, encoded solid phase libraries | |
AU756945B2 (en) | Color-encoding and in-situ interrogation of matrix-coupled chemical compounds | |
Jacobs et al. | Combinatorial chemistry—applications of light-directed chemical synthesis | |
US5840485A (en) | Topologically segregated, encoded solid phase libraries | |
Barnes et al. | Recent developments in the encoding and deconvolution of combinatorial libraries | |
WO2003038558A2 (en) | Device and methods for directed synthesis of chemical libraries | |
Hlavac et al. | Practical aspects of combinatorial solid-phase synthesis | |
Schmuck et al. | The development of artificial receptors for small peptides using combinatorial approaches | |
US20050095638A1 (en) | Factorial chemical libraries | |
US20050100968A1 (en) | Self-encoded combinatorial synthesis of compound multiplets | |
WO2023100976A1 (en) | Peptide-immobilized bead library | |
WO1997029371A1 (en) | Sulfur ratio tagging method for combinatorial libraries | |
Krämer et al. | Encoding technologies | |
Kushwaha et al. | A Novel Methods Used in Drug Discovery | |
Lebl et al. | Felder zyxwvutsrqponmlkj | |
G Newton | Editorial Biologicals & Immunologicals: Patenting combinatorial libraries and associated technologies | |
Ambre et al. | Combinatorial Chemistry: Role in Lead Discovery | |
CA2392919A1 (en) | Systems and methods to facilitate multiple order combinatorial chemical processes | |
US20030211536A1 (en) | Systems and methods to facilitate multiple order combinatorial chemical processes | |
Li | How to Optimize Reactions for Solid-Phase Synthesis of Combinatorial Libraries Using RF-Tagged Microreactors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US US US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08537752 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995920576 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995920576 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995920576 Country of ref document: EP |